Key result
Extended treatment with low-molecular-weight heparins for weeks or months is effective and safe for venous thromboembolism prophylaxis, secondary prevention of deep vein thrombosis, and during pregnancy.
Why the study?
Does extended duration of low-molecular-weight heparins provide effective and safe prophylaxis and treatment in patients with VTE, CAD, or during pregnancy?
Population
Patients requiring prophylaxis or treatment for venous thromboembolism, coronary artery disease, or during…
Comparison
Extended duration of low-molecular-weight heparins vs Oral anticoagulants or standard duration
Design
Review
Authors
Loading...
May guide LMWH selection for extended VTE prevention in pregnancy; leaves open head-to-head trials versus oral agents.
Does extended duration of low-molecular-weight heparins provide effective and safe prophylaxis and treatment in patients with VTE, CAD, or during pregnancy?
Extended duration of low-molecular-weight heparins is a safe and effective alternative to oral anticoagulants for prolonged VTE prophylaxis and treatment across various clinical scenarios.
Kher et al. (2001) conducted a review in Venous thromboembolism and coronary artery disease. Low-molecular-weight heparins (LMWHs) vs. Oral anticoagulants was evaluated. Extended treatment with low-molecular-weight heparins for weeks or months is effective and safe for venous thromboembolism prophylaxis, secondary prevention of deep vein thrombosis, and during pregnancy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: